Related Experiment Video
Updated: Jun 2, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Non-major histocompatibility complex rheumatoid arthritis susceptibility genes
Manfred Kunz1, Saleh M Ibrahim
1Department of Dermatology, Venereology and Allergology, University of Leipzig, Leipzig, Germany.
Critical Reviews in Immunology
|May 6, 2011
Summary
Genetic studies reveal non-major histocompatibility complex (MHC) genes like PTPN22 are crucial in rheumatoid arthritis (RA) pathogenesis. These findings suggest shared mechanisms in autoimmune diseases and potential new biologic therapies for RA.
Area of Science:
- Immunogenetics
- Rheumatology
- Genomics
Background:
- Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease with a significant genetic component.
- Genome-wide association studies (GWAS) have identified numerous RA susceptibility genes.
- Historically, the major histocompatibility complex (MHC) locus was considered the primary genetic contributor to RA.
Purpose of the Study:
- To review current knowledge on the role of non-MHC genes in rheumatoid arthritis pathogenesis.
- To highlight key non-MHC genes implicated in RA, such as PTPN22, CD40, STAT4, PRM1, and TNFAIP3.
- To explore the implications of genetic findings for understanding common autoimmune disease mechanisms and developing novel therapeutic strategies.
Main Methods:
- Review of recent genetic and treatment studies.
- Analysis of genome-wide association studies (GWAS) data.
- Identification and discussion of candidate genes outside the MHC locus.
Main Results:
- Significant genetic background identified for rheumatoid arthritis (RA).
- Key non-MHC genes (PTPN22, CD40, STAT4, PRM1, TNFAIP3) implicated in RA pathogenesis.
- Overlapping susceptibility genes suggest shared mechanisms across autoimmune diseases like SLE and type 1 diabetes.
Conclusions:
- Non-MHC genes play a critical role in RA pathogenesis, challenging the historical focus on the MHC locus.
- Genetic insights into RA offer potential for targeted biologic therapies by addressing overactive immune pathways.
- Further research is needed to enhance the predictive value of genetic polymorphisms in RA.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...